The resolution requires an official announcement from Google or its subsidiaries, such as DeepMind, explicitly stating that AlphaFold 4 is already developed (not still in development).
1,000A resolution wrinkle worth pricing: the AlphaFold lineage may have moved behind a wall. On 10 February 2026 Isomorphic Labs (the DeepMind spin-off) published a 27-page technical report on IsoDDE, its drug-design engine, which outside scientists described as "on the scale of an AlphaFold 4" (Scientific American), but it is proprietary, the company says it will not release the methods, and it is not called AlphaFold. AlphaFold 3 itself (Nature, May 2024) was released as code only in November 2024 and only for non-commercial use, already a step back from AlphaFold 2's full release. So the question for this market is less whether a next model exists than whether Google or DeepMind ever attaches the AlphaFold name to one publicly, now that the commercial value sits in Isomorphic ($2.1B raised in May 2026, first candidates due in the clinic by end of 2026). The step none of these models shorten is the in-vivo one; for aging indications the fastest such evidence outside mice comes from dogs, which is where the first lifespan trials of such drugs are running (mine): https://w0lph.github.io/k9/trials/
